Los Angeles Capital Management LLC Decreases Holdings in NeoGenomics, Inc. (NASDAQ:NEO)

Los Angeles Capital Management LLC lessened its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 70,331 shares of the medical research company’s stock after selling 4,302 shares during the period. Los Angeles Capital Management LLC owned about 0.05% of NeoGenomics worth $1,159,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock worth $30,000 after buying an additional 1,142 shares during the last quarter. Quarry LP purchased a new stake in NeoGenomics during the third quarter worth about $40,000. Blue Trust Inc. increased its holdings in NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock worth $46,000 after buying an additional 987 shares during the last quarter. KBC Group NV raised its stake in NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,127 shares during the period. Finally, FMR LLC raised its stake in NeoGenomics by 7.6% in the 3rd quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 931 shares during the period. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on NEO shares. Needham & Company LLC lowered their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, February 19th. Bank of America lowered their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 19th. Piper Sandler lowered their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating on the stock in a research note on Wednesday. The Goldman Sachs Group lowered their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.60.

NeoGenomics Stock Performance

NASDAQ:NEO opened at $9.99 on Friday. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The business’s 50-day moving average price is $14.49 and its two-hundred day moving average price is $15.24. The stock has a market cap of $1.28 billion, a P/E ratio of -16.11 and a beta of 1.23. NeoGenomics, Inc. has a twelve month low of $9.59 and a twelve month high of $19.11.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The company had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. As a group, equities analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.